The current acute treatments for migraines have shown efficacy and safety, however, approximately one-third of people do not respond, cannot use these options due to contraindications, or report dissatisfaction in therapy.
Melissa Yokoyama, PharmD Candidate
Advertisement
Articles by Melissa Yokoyama, PharmD Candidate
Advertisement
Latest Updated Articles
New Migraine Drugs Target Triptan Contraindication PopulationPublished: November 5th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
UConn’s Medical Writing Certificate Program: It’s Just "Write"
3
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
4
Pharmacy Policy Updates for October 2025
5
